E Fund Management Co. Ltd. Acquires New Stake in Arrowhead Pharmaceuticals, Inc. $ARWR

Key Points

• E Fund Management Co. Ltd. purchased 18,017 shares of Arrowhead Pharmaceuticals during the first quarter, amounting to approximately $230,000.
• Several institutional investors have increased their stakes in Arrowhead, with notable increases including GAMMA Investing LLC boosting their position by 297.6% and Principal Financial Group Inc. increasing by 117.8%.
• Analysts rate Arrowhead Pharmaceuticals as a "Moderate Buy" with an average price target of $43.14, despite some recent downgrades and a reported earnings miss.

E Fund Management Co. Ltd. acquired a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 18,017 shares of the biotechnology company's stock, valued at approximately $230,000.

Other institutional investors also recently bought and sold shares of the company. GAMMA Investing LLC grew its holdings in Arrowhead Pharmaceuticals by 297.6% in the first quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company's stock valued at $28,000 after purchasing an additional 1,628 shares during the period. GF Fund Management CO. LTD. acquired a new stake in shares of Arrowhead Pharmaceuticals in the fourth quarter worth approximately $49,000. CWM LLC boosted its stake in shares of Arrowhead Pharmaceuticals by 134.3% in the first quarter. CWM LLC now owns 4,401 shares of the biotechnology company's stock worth $56,000 after acquiring an additional 2,523 shares during the last quarter. KBC Group NV boosted its stake in shares of Arrowhead Pharmaceuticals by 40.8% in the first quarter. KBC Group NV now owns 7,356 shares of the biotechnology company's stock worth $94,000 after acquiring an additional 2,132 shares during the last quarter. Finally, XTX Topco Ltd acquired a new stake in shares of Arrowhead Pharmaceuticals in the first quarter worth approximately $133,000. 62.61% of the stock is owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Trading Up 1.7%

Arrowhead Pharmaceuticals stock traded up $0.34 during trading on Wednesday, reaching $20.20. 2,115,980 shares of the company were exchanged, compared to its average volume of 2,327,139. Arrowhead Pharmaceuticals, Inc. has a 52-week low of $9.57 and a 52-week high of $27.34. The company has a market capitalization of $2.79 billion, a P/E ratio of -15.78 and a beta of 0.94. The company has a debt-to-equity ratio of 0.39, a current ratio of 4.87 and a quick ratio of 4.87. The stock's 50 day simple moving average is $16.90 and its two-hundred day simple moving average is $15.94.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last posted its earnings results on Thursday, August 7th. The biotechnology company reported ($1.26) EPS for the quarter, missing analysts' consensus estimates of ($0.94) by ($0.32). The business had revenue of $27.77 million during the quarter, compared to the consensus estimate of $29.01 million. During the same quarter in the prior year, the company earned ($1.38) EPS. On average, equities research analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Citigroup lowered their price target on Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating on the stock in a research note on Tuesday, May 13th. HC Wainwright reaffirmed a "buy" rating and issued a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, May 20th. Wall Street Zen lowered Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Friday, July 18th. TD Cowen raised Arrowhead Pharmaceuticals to a "strong-buy" rating in a research note on Monday, July 28th. Finally, Royal Bank Of Canada lowered their price target on Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an "outperform" rating on the stock in a research note on Friday, August 8th. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $43.14.

Insider Buying and Selling

In other Arrowhead Pharmaceuticals news, insider James C. Hamilton sold 9,389 shares of Arrowhead Pharmaceuticals stock in a transaction on Friday, August 15th. The stock was sold at an average price of $20.00, for a total value of $187,780.00. Following the sale, the insider owned 262,122 shares in the company, valued at $5,242,440. The trade was a 3.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 4.30% of the stock is owned by corporate insiders.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.